hydrochlorothiazide has been researched along with simvastatin in 40 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.50) | 18.2507 |
| 2000's | 13 (32.50) | 29.6817 |
| 2010's | 23 (57.50) | 24.3611 |
| 2020's | 3 (7.50) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bentivoglio, M; Berioli, S; Conti, R; Corea, L; Osanna, RA; Savino, K; Zollino, L | 1 |
| White, KL | 1 |
| Bajraktari, G; Beqiri, A; Berisha, I; Elezi, S; Kastrati, S; Manaj, R; Thaqi, S | 1 |
| Borgström, F; Jönsson, B; Kanis, JA; Ström, O; Zethraeus, N | 1 |
| Kumar, V; Shah, RP; Singh, S | 1 |
| Afzal, R; Pais, P; Pogue, J; Sigamani, A; Xavier, D; Yusuf, S | 1 |
| Avorn, J; Brookhart, MA; Brown, TV; Choudhry, NK; Glynn, RJ; Jolda, C; Lee, TH; Schneeweiss, S; Shrank, WH; Snedden, TM; Solomon, DH; Spetman, M | 1 |
| Afzal, R; Eikelboom, J; Gupta, R; Mohan, V; Pais, P; Sigamani, A; Teo, K; Thomas, N; Xavier, D; Yusuf, S | 1 |
| Chakraborty, BS; Desai, J; Ghosh, C; Jha, V; Khamar, B; Patel, A; Shah, G; Shah, T | 1 |
| Dissanayake, WP; Furberg, CD; Gunaratne, PS; Jayasingne, IK; Mendis, S; Soliman, EZ; Somasundaram, NP | 1 |
| Balink, H; de Graaf, W; Grond, J; Hemmelder, MH | 1 |
| Armendaris, MK; Beck, AL; D'Avila, LB; Netto, FM; Otto, ME; Sposito, AC | 1 |
| Carey, KM; Comee, MR; Donovan, JL; Kanaan, AO | 1 |
| Afzal, R; Gao, P; Pais, P; Sigamani, A; Teo, KK; Xavier, D; Yusuf, S | 1 |
| Morris, JK; Wald, DS; Wald, NJ | 1 |
| Bots, ML; Grobbee, DE; Lafeber, M; Rodgers, A; Spiering, W; Thom, S; Visseren, FL; Webster, R | 1 |
| Shi, J; Wang, L; Zhang, Y | 1 |
| Billot, L; Bompoint, S; Bots, ML; Cidambi, R; Field, J; Grobbee, DE; Patel, A; Poulter, N; Prabhakaran, D; Reddy, KS; Rodgers, A; Stanton, A; Thom, S | 1 |
| Billot, L; Bompoint, S; Brown, A; Burch, C; Burke, H; Cass, A; Hayman, N; Hillis, GS; Jan, S; Molanus, B; Neal, B; Patel, A; Peiris, D; Rafter, N; Reid, CM; Rodgers, A; Shiel, L; Togni, S; Tonkin, A; Usherwood, T; Webster, R | 1 |
| Arroll, B; Bramley, D; Bryant, L; Bullen, C; Crengle, S; Doughty, RN; Elley, CR; Harwood, M; Jackson, R; Milne, RJ; Parag, V; Rafter, N; Rodgers, A; Selak, V; Wadham, A | 1 |
| Bots, ML; Grobbee, DE; Lafeber, M; Rodgers, A; Spiering, W; Visseren, FLj; Webster, R | 1 |
| Luteijn, JM; Morris, JK; Oppenheimer, P; Taylor, D; Wald, NJ | 1 |
| Luteijn, JM; Morris, JK; Wald, NJ | 1 |
| Agarwal, I; Ferket, BS; Fleischmann, KE; Hunink, MG; Khanji, M; Petersen, SE | 1 |
| Bots, ML; Grobbee, DE; Lafeber, M; Patel, A; Prabhakaran, D; Rodgers, A; Spiering, W; Stanton, A; Thom, S; Visseren, FL; Webster, R | 1 |
| Cheruvu, HS; Devalapalli, MMR; Sampathi, S; Shivakumar, S; Veeravalli, VB; Yertha, T | 1 |
| Bosch, J; Dans, AL; Gamra, H; Gao, P; Joseph, P; Lopez, PC; Lopez-Jaramillo, P; Pais, P; Santoso, A; Talukder, S; Teo, K; Tyrwhitt, J; Xavier, D; Yeates, K; Yusoff, K; Yusuf, S | 1 |
| Abdulwahab, S; Eissa, MS; Elsonbaty, A; Hassan, WS; Serag, A | 1 |
| Bosch, J; Christou, C; Dagenais, G; Dans, A; Gamra, H; Gao, P; Girish, P; Joseph, P; López-Jaramillo, P; McCready, T; Pais, P; Rocha, C; Santoso, A; Talukder, S; Teo, K; Tyrwhitt, J; Xavier, D; Xavier, F; Yeates, K; Yusoff, K; Yusuf, S | 1 |
| Ferguson, S; Healy, AM; Myślińska, M; Stocker, MW | 1 |
2 review(s) available for hydrochlorothiazide and simvastatin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke.
Topics: Antihypertensive Agents; Aspirin; Atenolol; Cardiovascular Diseases; Drug Combinations; Humans; Hydrochlorothiazide; Hypolipidemic Agents; Platelet Aggregation Inhibitors; Primary Prevention; Ramipril; Simvastatin; Stroke | 2012 |
18 trial(s) available for hydrochlorothiazide and simvastatin
| Article | Year |
|---|---|
[Simvastatin versus gemfibrozil in the treatment of primary hypercholesterolemia in hypertensive patients treated with hydrochlorothiazide].
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Female; Gemfibrozil; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Lipoproteins, HDL; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1990 |
The need to test the theories behind the Polypill: rationale behind the Indian Polycap Study.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atenolol; Capsules; Cardiovascular Agents; Cardiovascular Diseases; Diuretics; Double-Blind Method; Drug Combinations; Drug Costs; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; India; Platelet Aggregation Inhibitors; Primary Prevention; Ramipril; Research Design; Secondary Prevention; Simvastatin; Treatment Outcome | 2009 |
Rationale and design of the Study Assessing the Effect of Cardiovascular Medications Provided as Low-cost, Evidence-based Generic Samples (SAMPLES) trial.
Topics: Diuretics; Drug Costs; Drug Prescriptions; Drugs, Generic; Humans; Hydrochlorothiazide; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Pennsylvania; Physicians, Family; Prescription Drugs; Simvastatin | 2009 |
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aspirin; Atenolol; Cardiovascular Diseases; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; India; Middle Aged; Platelet Aggregation Inhibitors; Ramipril; Risk Factors; Risk Reduction Behavior; Simvastatin; Treatment Outcome | 2009 |
Preservation of bioavailability of ingredients and lack of drug-drug interactions in a novel five-ingredient polypill (polycap): a five-arm phase I crossover trial in healthy volunteers.
Topics: Administration, Oral; Adolescent; Adult; Antihypertensive Agents; Area Under Curve; Aspirin; Atenolol; Biological Availability; Capsules; Cardiovascular Diseases; Chromatography, Liquid; Cross-Over Studies; Drug Combinations; Drug Interactions; Humans; Hydrochlorothiazide; Hypolipidemic Agents; Male; Middle Aged; Platelet Aggregation Inhibitors; Ramipril; Risk Factors; Simvastatin; Tandem Mass Spectrometry; Young Adult | 2010 |
A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Attitude of Health Personnel; Biomarkers; Blood Pressure; Cardiovascular Agents; Cardiovascular Diseases; Chi-Square Distribution; Cholesterol; Diuretics; Drug Combinations; Feasibility Studies; Female; Health Knowledge, Attitudes, Practice; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lisinopril; Male; Medication Adherence; Middle Aged; Platelet Aggregation Inhibitors; Primary Prevention; Risk Assessment; Risk Factors; Simvastatin; Sri Lanka; Surveys and Questionnaires; Time Factors; Treatment Outcome; World Health Organization | 2011 |
Diastolic function parameters are improved by the addition of simvastatin to enalapril-based treatment in hypertensive individuals.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biomarkers; Blood Pressure; Brazil; Chi-Square Distribution; Cholesterol; Diastole; Diuretics; Double-Blind Method; Drug Therapy, Combination; Echocardiography, Doppler; Enalapril; Female; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Prospective Studies; Regression Analysis; Simvastatin; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left | 2012 |
Comparison of risk factor reduction and tolerability of a full-dose polypill (with potassium) versus low-dose polypill (polycap) in individuals at high risk of cardiovascular diseases: the Second Indian Polycap Study (TIPS-2) investigators.
Topics: Administration, Oral; Aged; Analysis of Variance; Antihypertensive Agents; Aspirin; Atenolol; Biomarkers; Blood Pressure; Capsules; Cardiovascular Diseases; Cholesterol, LDL; Creatinine; Dietary Supplements; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Female; Heart Rate; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; India; Male; Middle Aged; Platelet Aggregation Inhibitors; Polypharmacy; Potassium; Ramipril; Risk Assessment; Risk Factors; Simvastatin; Tablets; Time Factors; Treatment Outcome | 2012 |
Randomized Polypill crossover trial in people aged 50 and over.
Topics: Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypercholesterolemia; Hypertension; Losartan; Male; Middle Aged; Placebos; Simvastatin | 2012 |
The evening versus morning polypill utilization study: the TEMPUS rationale and design.
Topics: Administration, Oral; Antihypertensive Agents; Aspirin; Biomarkers; Blood Platelets; Blood Pressure; Cardiovascular Diseases; Cholesterol, LDL; Clinical Protocols; Cross-Over Studies; Drug Chronotherapy; Drug Combinations; Dyslipidemias; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Lisinopril; Netherlands; Platelet Aggregation Inhibitors; Primary Prevention; Prospective Studies; Research Design; Simvastatin; Tablets; Time Factors; Treatment Outcome | 2014 |
Influences of simvastatin on vascular endothelial function of patients with coronary heart disease complicated with congestive heart failure.
Topics: Adult; Aged; Calcitonin Gene-Related Peptide; Coronary Disease; Digoxin; Drug Therapy, Combination; Endothelins; Endothelium, Vascular; Female; Heart Failure; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Isosorbide Dinitrate; Male; Middle Aged; Nitric Oxide; Simvastatin | 2013 |
Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atenolol; Blood Pressure; Cardiovascular Diseases; Cholesterol, LDL; Drug Combinations; Female; Humans; Hydrochlorothiazide; Lisinopril; Male; Medication Adherence; Middle Aged; Platelet Aggregation Inhibitors; Risk Factors; Simvastatin; Treatment Outcome | 2013 |
A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk.
Topics: Administration, Oral; Adrenergic beta-1 Receptor Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aspirin; Atenolol; Australia; Biomarkers; Blood Pressure; Cardiovascular Diseases; Cholesterol; Drug Combinations; Drugs, Generic; Female; General Practice; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Lisinopril; Male; Middle Aged; Platelet Aggregation Inhibitors; Polypharmacy; Primary Prevention; Prospective Studies; Risk Factors; Simvastatin; Sodium Chloride Symporter Inhibitors; Tablets; Time Factors; Treatment Outcome | 2015 |
Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lisinopril; Male; Medication Adherence; Middle Aged; New Zealand; Primary Health Care; Regression Analysis; Risk Factors; Simvastatin; Young Adult | 2014 |
Estimated cardiovascular relative risk reduction from fixed-dose combination pill (polypill) treatment in a wide range of patients with a moderate risk of cardiovascular disease.
Topics: Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Agents; Cardiovascular Diseases; Diuretics; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Global Health; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lisinopril; Male; Medication Adherence; Middle Aged; Morbidity; Risk Assessment; Risk Factors; Simvastatin; Time Factors; Treatment Outcome | 2016 |
Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk.
Topics: Administration, Oral; Aged; Antihypertensive Agents; Aspirin; Atenolol; Biomarkers; Blood Pressure; Cardiovascular Diseases; Cholesterol, LDL; Drug Combinations; Drug Substitution; Europe; Female; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; India; Lisinopril; Male; Medication Adherence; Middle Aged; Platelet Aggregation Inhibitors; Polypharmacy; Risk Assessment; Risk Factors; Simvastatin; Tablets; Time Factors; Treatment Outcome | 2017 |
The International Polycap Study-3 (TIPS-3): Design, baseline characteristics and challenges in conduct.
Topics: Adrenergic beta-1 Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Diuretics; Double-Blind Method; Drug Combinations; Female; Global Health; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Primary Prevention; Ramipril; Retrospective Studies; Simvastatin | 2018 |
Polypill with or without Aspirin in Persons without Cardiovascular Disease.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atenolol; Blood Pressure; Cardiovascular Diseases; Cholesterol, LDL; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Incidence; Male; Medication Adherence; Middle Aged; Platelet Aggregation Inhibitors; Risk Factors; Simvastatin | 2021 |
20 other study(ies) available for hydrochlorothiazide and simvastatin
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Psoriasis and psoriatic arthritis, axial type.
Topics: Antihypertensive Agents; Arthritis, Psoriatic; Etanercept; Humans; Hydrochlorothiazide; Hypolipidemic Agents; Immunoglobulin G; Lisinopril; Male; Middle Aged; Psoriasis; Receptors, Tumor Necrosis Factor; Simvastatin | 2001 |
Acute myocardial infarction in a patient with severe unrecognized mitral stenosis.
Topics: Analgesics; Anti-Arrhythmia Agents; Anticholesteremic Agents; Anticoagulants; Aspirin; Atrial Fibrillation; Diuretics; Echocardiography, Transesophageal; Electrocardiography; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Hydrochlorothiazide; Metoprolol; Middle Aged; Mitral Valve Stenosis; Myocardial Infarction; Nadroparin; Simvastatin; Time Factors; Treatment Outcome | 2006 |
The cost-effectiveness of the treatment of high risk women with osteoporosis, hypertension and hyperlipidaemia in Sweden.
Topics: Aged; Aged, 80 and over; Alendronate; Antihypertensive Agents; Bone Density Conservation Agents; Cost-Benefit Analysis; Female; Health Care Costs; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Middle Aged; Models, Econometric; Osteoporosis, Postmenopausal; Quality-Adjusted Life Years; Simvastatin; Sweden | 2008 |
LC and LC-MS methods for the investigation of polypills for the treatment of cardiovascular diseases. Part 1. Separation of active components and classification of their interaction/degradation products.
Topics: Aspirin; Atenolol; Atorvastatin; Cardiovascular Agents; Chromatography, High Pressure Liquid; Drug Combinations; Drug Interactions; Drug Stability; Heptanoic Acids; Hydrochlorothiazide; Lisinopril; Pravastatin; Pyrroles; Simvastatin; Spectrometry, Mass, Electrospray Ionization | 2008 |
Scintigraphic diagnosis of Erdheim-Chester disease.
Topics: Aged; Amlodipine; Antihypertensive Agents; Diabetes Mellitus, Type 2; Drug Combinations; Erdheim-Chester Disease; Gated Blood-Pool Imaging; Humans; Hydrochlorothiazide; Hypoglycemic Agents; Hypolipidemic Agents; Imidazoles; Knee Joint; Losartan; Male; Metformin; Positron-Emission Tomography; Prostatic Neoplasms; Simvastatin | 2011 |
Cost-benefit analysis of the polypill in the primary prevention of myocardial infarction and stroke.
Topics: Aged; Aged, 80 and over; Amlodipine; Aspirin; Cardiovascular Agents; Case-Control Studies; Cohort Studies; Cost-Benefit Analysis; Humans; Hydrochlorothiazide; Losartan; Markov Chains; Middle Aged; Myocardial Infarction; Polypharmacy; Primary Prevention; Quality-Adjusted Life Years; Simvastatin; Stroke; United Kingdom | 2016 |
Starting the polypill: the use of a single age cut-off in males and females.
Topics: Adult; Age Factors; Aged; Cardiovascular Agents; Drug Combinations; Female; Humans; Hydrochlorothiazide; Losartan; Male; Middle Aged; Myocardial Infarction; Preventive Health Services; Simvastatin; State Medicine; Stroke; United Kingdom | 2017 |
Cost-effectiveness of the polypill versus risk assessment for prevention of cardiovascular disease.
Topics: Administration, Oral; Adult; Aged; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Computer Simulation; Cost-Benefit Analysis; Drug Combinations; Drug Costs; Dyslipidemias; Female; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Losartan; Male; Middle Aged; Models, Economic; Primary Prevention; Quality-Adjusted Life Years; Risk Assessment; Risk Factors; Simvastatin; Tablets; Time Factors; Treatment Outcome | 2017 |
Hansen solubility parameters for assay method optimization of simvastatin, ramipril, atenolol, hydrochlorothiazide and aspirin in human plasma using liquid chromatography with tandem mass spectrometry.
Topics: Aspirin; Atenolol; Chromatography, Liquid; Humans; Hydrochlorothiazide; Ramipril; Reproducibility of Results; Simvastatin; Solubility; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2017 |
Analysis of quinary therapy targeting multiple cardiovascular diseases using UV spectrophotometry and chemometric tools.
Topics: Algorithms; Aspirin; Atenolol; Capsules; Cardiovascular Diseases; Chromatography, High Pressure Liquid; Humans; Hydrochlorothiazide; Least-Squares Analysis; Ramipril; Simvastatin; Spectrophotometry, Ultraviolet | 2020 |
A Comparison of Spray-Drying and Co-Precipitation for the Generation of Amorphous Solid Dispersions (ASDs) of Hydrochlorothiazide and Simvastatin.
Topics: Calorimetry, Differential Scanning; Drug Compounding; Hydrochlorothiazide; Powders; Simvastatin; Solubility; Spray Drying; X-Ray Diffraction | 2023 |